Reply: DGUOK recessive mutations in patients with CPEO, mitochondrial myopathy, parkinsonism and mtDNA deletions by D. Ronchi et al.
  
 
 
 
 
 
 
 
 
Reply: DGUOK recessive mutations in patients with CPEO, mitochondrial myopathy, 
parkinsonism and mtDNA deletions 
 
Dario Ronchi,1 Daniela Piga,1 Stefano Lamberti,1 Monica Sciacco,2 Stefania Corti,1 
Maurizio Moggio,2 Nereo Bresolin1 and Giacomo Pietro Comi1 
 
1 Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, 
Neurology Unit, IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy 
2 Neuromuscular and Rare Disease Unit, Department of Neuroscience, Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milano, 
Italy 
Correspondence to: Dario Ronchi 
University of Milan 
Department of Pathophysiology and Transplantation, Neuroscience Section 
IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 
20122 Milan, Italy 
E-mail: dario.ronchi@unimi.it 
 
 
Sir, 
We read with interest the letter from Caporali et  al. 
(2017) reporting three novel patients from two independent 
families displaying adult onset mitochondrial disorders due 
to recessive DGUOK mutations, confirming the findings of 
our original paper (Ronchi et al., 2012). Since then, the 
molecular  screening  of DGUOK in  our cohort  of  patients 
featuring the accumulation of multiple mitochondrial DNA 
(mtDNA) deletions in skeletal muscle has not detected add- 
itional cases. However, the use of traditional and next gen- 
eration sequencing (NGS) has expanded the number of 
variants  in  canonical  and  novel  genes  (Kornblum  et  al., 
2013; Ronchi et al., 2013, 2015; Reyes et al., 2015) asso- 
ciated with impaired muscle mtDNA maintenance  (Table 
1). DGUOK mutations now represent the 4.7% cause of 
disease in our cohort of patients and, considering the novel 
cases described by Caporali et al. (2017), they account for 
6.9% of adult patients with mtDNA maintenance  dis- 
orders in which a molecular diagnosis has been established 
(the third most frequent molecular defect after mutations in 
POLG and PEO1/TWNK encoding, respectively, for the 
mtDNA polymerase POLG and the helicase TWINKLE). 
Clinical features of the novel probands include progressive 
bilateral ptosis followed by muscle weakness in upper and 
lower limbs. Serum creatine kinase levels were found to be 
increased in two patients and reached large amounts 
episodically in Patient 3, similar to one of our cases. 
Interestingly the same patient displayed visual, auditory and 
CNS involvement. Neuroimaging demonstrated a diffuse 
hypometabolism in basal ganglia  and  extending  bilaterally  to 
the occipital cortex, as observed in other mitochondrial 
encephalomyopathies (Martikainen et al., 2016). DATscan 
showed a bilateral reduction of basal ganglia uptake. 
Consistently, clinical features of this patient included rigidity 
and bradykinesia but parkinsonism seems an isolated finding 
since   it   was   not   observed   in   other   DGUOK   patients. 
Nevertheless,   mutations   in  DGUOK  add  to  the   group of 
defects impairing mtDNA maintenance found to segregate 
with parkinsonism, which include POLG (Miguel et  al., 
2014), POLG2 (Van Maldergem et al.,  2016),  PEO1/  
TWNK (Kiferle et al., 2013), OPA1 (Carelli et al., 2015), 
MPV17 (Garone et al., 2012). Nigrostriatal dysfunction has 
been observed in vivo (Tzoulis et al., 2016) and ex vivo 
(Tzoulis et al., 2013) in patients harbouring  POLG  and  
PEO1 mutations as well as in transgenic mice selectively ex- 
pressing mutant forms of these enzymes in striatal midbrain 
neurons (Song et al., 2012; Perier et al., 2013). In this regard, 
the  massive  accumulation  of  mtDNA  deletions  in  the pro- 
band presenting parkinsonism supports the hypothesis that 
mtDNA homeostasis is essential for dopaminergic survival. 
The authors evaluated mtDNA content and integrity  by 
using standard techniques as well as digital PCR, an 
 
 
  
  
 
 
 
Table 1 Relative proportion of genetically diagnosed patients harboring muscle mtDNA deletions 
 
Patients Independent probands Familial cases Sporadic cases 
POLG 35 (27.6%) 24 (24.2%) 7 (22.6%) 17 (25.0%) 
TWNK/PEO1 18 (14.2%) 18 (18.2%) 13 (41.9%) 5 (7.4%) 
SLC25A4/ANT1 6 (4.7%) 6 (6.1%) 6 (19.4%) 0  
DGUOK 6 (4.7%) 5 (5.1%) 1 (3.2%) 4 (5.9%) 
DNA2 4 (2.7%) 3 (2.3%) 1 (3.2%) 2 (2%) 
TYMP 4 (3.1%) 2 (2.0%) 1 (3.2%) 1 (1.5%) 
OPA1 3 (2.4%) 3 (3.0%) 0  3 (4.4%) 
TK2 2 (1.6%) 2 (2.0%) 0  2 (2.9%) 
MGME1 2 (1.6%) 1 (1.0%) 1 (3.2%) 0  
RNASEH1 1 (0.8%) 1 (1.0%) 0  1 (1.5%) 
CHCHD10 1 (0.8%) 1 (1.0%) 0  1 (1.5%) 
Undiagnosed 45 (35.4%) 64 (33.3%) 1 (3.2%) 63 (47.1%) 
Total 127  99  31  68  
 
 
 
 
 
 
 
 
approach that combines superior sensitivity and absolute 
quantification of mtDNA molecules. These assays disclosed 
the co-occurrence of mtDNA depletion and deletions in pa- 
tients’ samples. This finding is consistent with the fundamen- 
tal role of deoxyguanosine kinase  in the  mitochondrial 
supply of dNTPs in post-mitotic tissues. Similarly, in our 
cohort of patients with mtDNA instability, a reduction in 
muscle mtDNA content was observed in subjects harbouring 
mutations in DGUOK and TK2 (two key enzymes of the 
dNTPs salvage pathway) but not  in patients  with  mutations 
in POLG or TWINKLE (mtDNA replisome machinery) or in 
a cohort of age-matched controls without neurological in- 
volvement (Fig. 1). Age at biopsy, the type of muscle 
sampled, the different patterns  of inheritance and  the 
number of patients analysed restricts the range of this finding. 
In conclusion, the study from Caporali et al. (2017) con- 
firms and expands the pathogenetic role of DGUOK dys- 
function in adult-onset mitochondrial presentations. The 
application of next generation sequencing in adult patients 
with mitochondrial phenotypes is expected to identify novel 
DGUOK cases in the future. In parallel, paediatric patients 
who  underwent  liver  transplantation  because  of DGUOK- 
related hepatocerebral mtDNA depletion syndrome are can- 
didates to develop some of the neurological symptoms here 
described. These findings reinforce the paradigm according 
to which defects in the same gene might result in a spec- 
trum of clinical conditions ranging from severe early-onset 
syndromes to milder adult-onset presentations according to 
the behaviour of the causative mutations (and the relative 
residual enzymatic activities in affected tissues) (Viscomi 
and Zeviani, 2017). The existence of common mechanisms 
for such heterogeneous conditions lays the basis for the 
development of shared therapies. For  DGUOK  patients, 
the effects of nucleosides supplementation in symptomatic 
patients, or even before symptoms onset, should be con- 
sidered in view of the encouraging results obtained in pre- 
clinical studies addressing other forms of mtDNA instability 
(Ca´mara et al., 2014; Lopez-Gomez et al., 2017). 
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Figure 1 Box plot showing muscle mtDNA content in 
adult patients featuring mitochondrial myopathy with 
muscle mtDNA deletions associated with mutations in 
POLG or TWNK/PEO1 (n = 33) and DGUOK or TK2 (n = 7) 
compared with healthy controls (n = 27). Solid bars represent 
median values. mtDNA quantification, normalized to nuclear DNA 
(nDNA) content, was performed by quantitative real-time PCR as 
previously described (Spinazzola et al., 2006). Mitochondrial DNA 
content in DGUOK/TK2 patients was significantly reduced compared 
to POLG1/PEO1 patients (t-test, P 5 0.05) and control subjects (t- 
test, P 5 0.01). 
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